NeuroPace, Inc. cash flow to debt ratio of -15.54% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

NeuroPace, Inc.'s free cash flow has increased -37.89% from $-18.25M last year to $-11.34M, signaling increasing performance

NeuroPace, Inc.'s debt to equity ratio is 4.87, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

NeuroPace, Inc.'s debt has decreased relative to shareholder equity from 9.15 last year to 4.87 today, signaling strengthened financials

NeuroPace, Inc. has negative EBITDA, making leverage ratio unreliable

NeuroPace, Inc.'s interest coverage ratio is -2.46, which means that the company struggles to meet interest obligations, signaling financial risk.

NeuroPace, Inc.'s profit margin has increased (-36.21%) in the last year from -33.97% to -21.67%, signaling increasing performance

NeuroPace, Inc.'s short-term assets of $94.07M exceed its short-term liabilities of $17.81M

NeuroPace, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

NeuroPace, Inc.'s return on equity of -120.74%, is lower than 15.00%, indicating bad performance

NeuroPace, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

NeuroPace, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

NeuroPace, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

NeuroPace, Inc. has negative free cash flow, indicating cash burn

NeuroPace, Inc.'s yearly earnings has increased -20.91% since last year from $-27.14M to $-21.46M, signaling increasing performance

NeuroPace, Inc.'s yearly revenue has increased 25.13% since last year from $79.91M to $99.99M, signaling increasing performance

ROIC -19.74% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

NeuroPace, Inc.'s 3-year revenue CAGR of 29.99% is positive, indicating growing revenue over the past 3 years

NeuroPace, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

NeuroPace, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

NeuroPace, Inc. has insufficient data to evaluate this check.

NeuroPace, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

NeuroPace, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

NeuroPace, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

NeuroPace, Inc. has insufficient data to evaluate this check.

NeuroPace, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

NeuroPace, Inc. has a price-to-book ratio of 38.42x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

NeuroPace, Inc. has a price-to-sales ratio of 5.64x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue